arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BOSTON SCIENTIFIC CORP

BSX
$44.63 ▼ -1.19 (-2.60%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
20 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Neutral
auto_awesome

Analytical Summary

BOSTON SCIENTIFIC CORP shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $66.1B
Dividend Yield —
Revenue Growth 19.9% ↗
Op. Margin 18.0% ↗
ROIC 12.7% ↗
FCF / Share $2.47 ↗
Trailing P/E 22.8x
Price / Book 2.7x
FCF Yield 5.5%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.07B
↑ +19.9% —
Net Income Profit after all expenses
$2.89B
↑ +56.7% —
Operating Margin Operating profit as % of sales
18.0%
↑ +15.8% 72th
FCF / Share Free cash flow per share
$2.47
↑ +37.5% —
Long-Term Debt Long-term obligations
$3.81B
↓ -29.4% —

Health Breakdown

Profitability ↑
75
Returns ↑
74
Financial Health ↑
83
Cash Quality →
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters